Tamoxifen in breast cancer survivors with COVID 19: stop or go?

Med Oncol. 2021 Mar 17;38(4):42. doi: 10.1007/s12032-021-01492-z.

Authors

Cengiz Karacin¹, Pinar Karacin², Yakup Ergun³

Affiliations

¹ Department of Medical Oncology, Recep Tayyip Erdoğan University, Rize, Turkey. [email protected].
² Department of Gynecology and Obstetrics, Recep Tayyip Erdoğan University, Rize, Turkey.
³ Department of Medical Oncology, Batman Training and Research Hospital, Batman, Turkey.

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents, Hormonal / therapeutic use*
Breast / drug effects
Breast / virology
Breast Neoplasms / drug therapy*
Breast Neoplasms / virology
COVID-19 / complications*
COVID-19 / virology
Cancer Survivors
Female
Humans
Tamoxifen / therapeutic use*
Venous Thromboembolism / etiology
Venous Thromboembolism / virology

Substances

Antineoplastic Agents, Hormonal
Tamoxifen